No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EYEN Eyenovia
- 0.760
- -0.048-5.89%
Close Jun 3 16:00 ET
40.96MMarket Cap-1027P/E (TTM)
0.810High0.731Low410.29KVolume0.810Open0.808Pre Close312.40KTurnover0.97%Turnover RatioLossP/E (Static)53.87MShares2.97052wk High22.36P/B32.15MFloat Cap0.50152wk Low--Dividend TTM42.28MShs Float10.740Historical High--Div YieldTTM9.80%Amplitude0.501Historical Low0.761Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLiquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion. Adagene (NASDAQ:ADAG) shares moved upward
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
Earnings Call Summary | Eyenovia(EYEN.US) Q1 2024 Earnings Conference
The following is a summary of the Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript:Financial Performance:Eyenovia reported a Q1 2024 net loss of about $10.9 million or $0.23 per share. This incl
Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results.Fluent posted adjusted loss of 30 cents per share, versus market expectat
SYTA, DATS and CYN Among Mid-day Movers
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
Comments
$Eyenovia(EYEN.US$ HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
$Eyenovia(EYEN.US$ Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $4.993 thousand which missed the analyst consensus estimate of $816.667 thousand by 99.39 percent.
2
$Eyenovia(EYEN.US$ Reuters· just
Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
$Eyenovia(EYEN.US$ Well im taking this for a earnings spin! Hehehe! Wish me luck! I know that next Q will probably be much better because of some things not yet settled? But i really like it and if my earnings spin crashes? Well no harm because ive traded it before and i like it! So ill just swing it! Hehehe! NFA![]()
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg